Singapore markets close in 4 hours 46 minutes

MannKind Corporation (MNKD)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.1500-0.0100 (-0.24%)
At close: 4:00PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close4.1600
Bid4.0900 x 1800
Ask4.1000 x 47300
Day's range4.0700 - 4.3020
52-week range1.9400 - 6.2500
Avg. volume2,865,730
Market cap1.036B
Beta (5Y monthly)1.93
PE ratio (TTM)N/A
EPS (TTM)-0.3590
Earnings date02 Nov 2021 - 08 Nov 2021
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est6.17
  • Zacks

    United Therapeutics' (UTHR) Tyvaso DPI NDA Gets CRL From FDA

    United Therapeutics' (UTHR) new drug application for Tyvaso DPI to treat PAH & PH-ILD fails to secure approval from the FDA. The stock declines resultantly.

  • Motley Fool

    Why Shares of MannKind Corporation Are Falling This Morning

    Shares of MannKind (NASDAQ: MNKD), a company working to develop inhaled therapeutics, were down 18% as of 11:59 a.m. EDT on Monday after an inspection issue derailed its hopes of approval for Tyvaso DPI, a lung disease therapy it developed with United Therapeutics (NASDAQ: UTHR). According to United Therapeutics' Securities and Exchange Commission filings, it owns two patents for treating PAH through inhalation that expire in 2024. The Food and Drug Administration's complete response letter didn't cite issues with MannKind's operations or even the clinical data submitted by the two companies.